| Year |
Citation |
Score |
| 2017 |
Gufford BT, Ainslie GR, White JR, Layton ME, Padowski JM, Pollack GM, Paine MF. Comparison of a New Intranasal Naloxone Formulation to Intramuscular Naloxone: Results from Hypothesis-Generating Small Clinical Studies. Clinical and Translational Science. PMID 28504483 DOI: 10.1111/Cts.12473 |
0.746 |
|
| 2012 |
Padowski JM, Pollack GM. Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 40: 1846-53. PMID 22715475 DOI: 10.1124/Dmd.112.045500 |
0.801 |
|
| 2011 |
Padowski JM, Pollack GM. Influence of time to achieve substrate distribution equilibrium between brain tissue and blood on quantitation of the blood-brain barrier P-glycoprotein effect. Brain Research. 1426: 1-17. PMID 22036081 DOI: 10.1016/J.Brainres.2011.10.009 |
0.816 |
|
| 2011 |
Padowski JM, Pollack GM. The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue. Journal of Pharmacokinetics and Pharmacodynamics. 38: 743-67. PMID 21983688 DOI: 10.1007/S10928-011-9218-0 |
0.807 |
|
| 2011 |
Yan GZ, Brouwer KL, Pollack GM, Wang MZ, Tidwell RR, Hall JE, Paine MF. Mechanisms underlying differences in systemic exposure of structurally similar active metabolites: comparison of two preclinical hepatic models. The Journal of Pharmacology and Experimental Therapeutics. 337: 503-12. PMID 21320872 DOI: 10.1124/Jpet.110.177220 |
0.594 |
|
| 2010 |
Padowski JM, Pollack GM. Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein. Journal of Pharmaceutical Sciences. 99: 3226-33. PMID 20127824 DOI: 10.1002/Jps.22070 |
0.806 |
|
| 2010 |
Padowski JM, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Methods in Molecular Biology (Clifton, N.J.). 596: 359-84. PMID 19949932 DOI: 10.1007/978-1-60761-416-6_16 |
0.777 |
|
| 2009 |
Zhao R, Pollack GM. Regional differences in capillary density, perfusion rate, and P-glycoprotein activity: a quantitative analysis of regional drug exposure in the brain. Biochemical Pharmacology. 78: 1052-9. PMID 19523457 DOI: 10.1016/J.Bcp.2009.06.001 |
0.471 |
|
| 2009 |
Lee JK, Abe K, Bridges AS, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Sex-dependent disposition of acetaminophen sulfate and glucuronide in the in situ perfused mouse liver. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1916-21. PMID 19487254 DOI: 10.1124/Dmd.109.026815 |
0.566 |
|
| 2009 |
Kim S, Kim D, Pollack GM, Collins LB, Rusyn I. Pharmacokinetic analysis of trichloroethylene metabolism in male B6C3F1 mice: Formation and disposition of trichloroacetic acid, dichloroacetic acid, S-(1,2-dichlorovinyl)glutathione and S-(1,2-dichlorovinyl)-L-cysteine. Toxicology and Applied Pharmacology. 238: 90-9. PMID 19409406 DOI: 10.1016/J.Taap.2009.04.019 |
0.324 |
|
| 2009 |
Zhao R, Kalvass JC, Pollack GM. Assessment of blood-brain barrier permeability using the in situ mouse brain perfusion technique. Pharmaceutical Research. 26: 1657-64. PMID 19384470 DOI: 10.1007/S11095-009-9876-4 |
0.77 |
|
| 2009 |
Zhao R, Raub TJ, Sawada GA, Kasper SC, Bacon JA, Bridges AS, Pollack GM. Breast cancer resistance protein interacts with various compounds in vitro, but plays a minor role in substrate efflux at the blood-brain barrier. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 1251-8. PMID 19273529 DOI: 10.1124/Dmd.108.025064 |
0.483 |
|
| 2009 |
Zhao R, Kalvass JC, Yanni SB, Bridges AS, Pollack GM. Fexofenadine brain exposure and the influence of blood-brain barrier P-glycoprotein after fexofenadine and terfenadine administration. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 529-35. PMID 19114463 DOI: 10.1124/Dmd.107.019893 |
0.781 |
|
| 2009 |
Zamek-Gliszczynski MJ, Kalvass JC, Pollack GM, Brouwer KL. Relationship between drug/metabolite exposure and impairment of excretory transport function. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 37: 386-90. PMID 19022942 DOI: 10.1124/Dmd.108.023648 |
0.762 |
|
| 2008 |
Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. The Aaps Journal. 10: 537-51. PMID 18989788 DOI: 10.1208/S12248-008-9056-1 |
0.313 |
|
| 2008 |
Wolf KK, Brouwer KR, Pollack GM, Brouwer KL. Effect of albumin on the biliary clearance of compounds in sandwich-cultured rat hepatocytes. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 36: 2086-92. PMID 18653747 DOI: 10.1124/Dmd.108.020842 |
0.569 |
|
| 2008 |
Ghibellini G, Leslie EM, Pollack GM, Brouwer KL. Use of tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport: integration of in vitro, pharmacokinetic modeling, and simulation studies. Pharmaceutical Research. 25: 1851-60. PMID 18509604 DOI: 10.1007/S11095-008-9597-0 |
0.578 |
|
| 2008 |
Bauer B, Hartz AM, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme, GSTpi, at the blood-brain barrier. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 28: 1222-34. PMID 18349876 DOI: 10.1038/Jcbfm.2008.16 |
0.44 |
|
| 2007 |
Kalvass JC, Olson ER, Cassidy MP, Selley DE, Pollack GM. Pharmacokinetics and pharmacodynamics of seven opioids in P-glycoprotein-competent mice: assessment of unbound brain EC50,u and correlation of in vitro, preclinical, and clinical data. The Journal of Pharmacology and Experimental Therapeutics. 323: 346-55. PMID 17646430 DOI: 10.1124/Jpet.107.119560 |
0.798 |
|
| 2007 |
Tian X, Li J, Zamek-Gliszczynski MJ, Bridges AS, Zhang P, Patel NJ, Raub TJ, Pollack GM, Brouwer KL. Roles of P-glycoprotein, Bcrp, and Mrp2 in biliary excretion of spiramycin in mice. Antimicrobial Agents and Chemotherapy. 51: 3230-4. PMID 17576841 DOI: 10.1128/Aac.00082-07 |
0.637 |
|
| 2007 |
Kalvass JC, Maurer TS, Pollack GM. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 660-6. PMID 17237155 DOI: 10.1124/Dmd.106.012294 |
0.771 |
|
| 2007 |
Kalvass JC, Pollack GM. Kinetic considerations for the quantitative assessment of efflux activity and inhibition: implications for understanding and predicting the effects of efflux inhibition. Pharmaceutical Research. 24: 265-76. PMID 17191095 DOI: 10.1007/S11095-006-9135-X |
0.701 |
|
| 2007 |
Kalvass JC, Olson ER, Pollack GM. Pharmacokinetics and pharmacodynamics of alfentanil in P-glycoprotein-competent and P-glycoprotein-deficient mice: P-glycoprotein efflux alters alfentanil brain disposition and antinociception. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 35: 455-9. PMID 17178769 DOI: 10.1124/Dmd.106.011445 |
0.821 |
|
| 2006 |
Bauer B, Yang X, Hartz AM, Olson ER, Zhao R, Kalvass JC, Pollack GM, Miller DS. In vivo activation of human pregnane X receptor tightens the blood-brain barrier to methadone through P-glycoprotein up-regulation. Molecular Pharmacology. 70: 1212-9. PMID 16837625 DOI: 10.1124/Mol.106.023796 |
0.82 |
|
| 2006 |
Bourdet DL, Pollack GM, Thakker DR. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharmaceutical Research. 23: 1178-87. PMID 16741656 DOI: 10.1007/S11095-006-0204-Y |
0.339 |
|
| 2006 |
Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KL. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modeling in sandwich-cultured rat hepatocytes. The Journal of Pharmacology and Experimental Therapeutics. 318: 881-9. PMID 16690724 DOI: 10.1124/Jpet.106.102616 |
0.771 |
|
| 2005 |
Chandra P, Johnson BM, Zhang P, Pollack GM, Brouwer KL. Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1238-43. PMID 15908472 DOI: 10.1124/Dmd.105.003665 |
0.602 |
|
| 2005 |
Graff CL, Pollack GM. Nasal drug administration: potential for targeted central nervous system delivery. Journal of Pharmaceutical Sciences. 94: 1187-95. PMID 15858850 DOI: 10.1002/Jps.20318 |
0.803 |
|
| 2005 |
Graff CL, Zhao R, Pollack GM. Pharmacokinetics of substrate uptake and distribution in murine brain after nasal instillation. Pharmaceutical Research. 22: 235-44. PMID 15783071 DOI: 10.1007/S11095-004-1191-5 |
0.792 |
|
| 2005 |
Graff CL, Pollack GM. Functional evidence for P-glycoprotein at the nose-brain barrier. Pharmaceutical Research. 22: 86-93. PMID 15771234 DOI: 10.1007/S11095-004-9013-3 |
0.808 |
|
| 2005 |
Heinzen EL, Booth RG, Pollack GM. Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the mu-opioid receptor. Biochemical Pharmacology. 69: 679-88. PMID 15670586 DOI: 10.1016/J.Bcp.2004.11.004 |
0.62 |
|
| 2005 |
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5]enkephalin. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 287-93. PMID 15528320 DOI: 10.1124/Dmd.104.001420 |
0.615 |
|
| 2004 |
Kalvass JC, Graff CL, Pollack GM. Use of loperamide as a phenotypic probe of mdr1a status in CF-1 mice. Pharmaceutical Research. 21: 1867-70. PMID 15553234 DOI: 10.1023/B:Pham.0000045241.26925.8B |
0.788 |
|
| 2004 |
Heinzen EL, Pollack GM. Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Research. 1023: 175-84. PMID 15374743 DOI: 10.1016/J.Brainres.2004.07.015 |
0.622 |
|
| 2004 |
Matheny CJ, Ali RY, Yang X, Pollack GM. Effect of prototypical inducing agents on P-glycoprotein and CYP3A expression in mouse tissues. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 32: 1008-14. PMID 15319343 |
0.76 |
|
| 2004 |
Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KL. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. The Journal of Pharmacology and Experimental Therapeutics. 311: 1203-10. PMID 15302892 DOI: 10.1124/Jpet.104.070201 |
0.628 |
|
| 2004 |
Persky AM, Berry NS, Pollack GM, Brouwer KL. Modelling the cardiovascular effects of ephedrine. British Journal of Clinical Pharmacology. 57: 552-62. PMID 15089807 DOI: 10.1111/J.1365-2125.2003.02062.X |
0.546 |
|
| 2004 |
Graff CL, Pollack GM. Drug transport at the blood-brain barrier and the choroid plexus. Current Drug Metabolism. 5: 95-108. PMID 14965253 DOI: 10.2174/1389200043489126 |
0.784 |
|
| 2004 |
Heinzen EL, Pollack GM. The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. Biochemical Pharmacology. 67: 735-41. PMID 14757173 DOI: 10.1016/J.Bcp.2003.08.046 |
0.606 |
|
| 2004 |
Dagenais C, Graff CL, Pollack GM. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochemical Pharmacology. 67: 269-76. PMID 14698039 DOI: 10.1016/J.Bcp.2003.08.027 |
0.818 |
|
| 2003 |
Heinzen EL, Pollack GM. Pharmacokinetics and pharmacodynamics of L-arginine in rats: a model of stimulated neuronal nitric oxide synthesis. Brain Research. 989: 67-75. PMID 14519513 DOI: 10.1016/S0006-8993(03)03370-5 |
0.629 |
|
| 2003 |
Golden PL, Pollack GM. Blood-brain barrier efflux transport. Journal of Pharmaceutical Sciences. 92: 1739-53. PMID 12949994 DOI: 10.1002/Jps.10424 |
0.428 |
|
| 2003 |
Graff CL, Pollack GM. P-Glycoprotein attenuates brain uptake of substrates after nasal instillation. Pharmaceutical Research. 20: 1225-30. PMID 12948020 DOI: 10.1023/A:1025053115583 |
0.821 |
|
| 2003 |
Zong J, Pollack GM. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin. The Journal of Pharmacology and Experimental Therapeutics. 306: 556-62. PMID 12721332 DOI: 10.1124/Jpet.103.049452 |
0.695 |
|
| 2003 |
Zamek-Gliszczynski MJ, Xiong H, Patel NJ, Turncliff RZ, Pollack GM, Brouwer KL. Pharmacokinetics of 5 (and 6)-carboxy-2',7'-dichlorofluorescein and its diacetate promoiety in the liver. The Journal of Pharmacology and Experimental Therapeutics. 304: 801-9. PMID 12538836 DOI: 10.1124/Jpet.102.044107 |
0.613 |
|
| 2002 |
Heinzen EL, Pollack GM. Use of an electrochemical nitric oxide sensor to detect neuronal nitric oxide production in conscious, unrestrained rats. Journal of Pharmacological and Toxicological Methods. 48: 139-46. PMID 14986862 DOI: 10.1016/S1056-8719(03)00043-1 |
0.569 |
|
| 2002 |
Brouwer KL, Pollack GM. Pharmacogenetics: is the right drug for the right patient sufficient? Advanced Drug Delivery Reviews. 54: 1243-4. PMID 12406642 DOI: 10.1016/S0169-409X(02)00164-3 |
0.527 |
|
| 2002 |
Xiong H, Suzuki H, Sugiyama Y, Meier PJ, Pollack GM, Brouwer KL. Mechanisms of impaired biliary excretion of acetaminophen glucuronide after acute phenobarbital treatment or phenobarbital pretreatment. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 962-9. PMID 12167560 DOI: 10.1124/Dmd.30.9.962 |
0.6 |
|
| 2002 |
Murthy BR, Pollack GM, Brouwer KL. Contribution of morphine-6-glucuronide to antinociception following intravenous administration of morphine to healthy volunteers. Journal of Clinical Pharmacology. 42: 569-76. PMID 12017351 DOI: 10.1177/00912700222011508 |
0.579 |
|
| 2002 |
Dagenais C, Ducharme J, Pollack GM. Interaction of nonpeptidic delta agonists with P-glycoprotein by in situ mouse brain perfusion: liquid chromatography-mass spectrometry analysis and internal standard strategy. Journal of Pharmaceutical Sciences. 91: 244-52. PMID 11782913 DOI: 10.1002/Jps.1175 |
0.735 |
|
| 2001 |
Dagenais C, Zong J, Ducharme J, Pollack GM. Effect of mdr1a P-glycoprotein gene disruption, gender, and substrate concentration on brain uptake of selected compounds. Pharmaceutical Research. 18: 957-63. PMID 11496955 DOI: 10.1023/A:1010984110732 |
0.792 |
|
| 2001 |
Matheny CJ, Lamb MW, Brouwer KR, Pollack GM. Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation. Pharmacotherapy. 21: 778-96. PMID 11444575 DOI: 10.1592/Phco.21.9.778.34558 |
0.769 |
|
| 2001 |
Dagenais C, Ducharme J, Pollack GM. Uptake and efflux of the peptidic delta-opioid receptor agonist. Neuroscience Letters. 301: 155-8. PMID 11257421 DOI: 10.1016/S0304-3940(01)01640-8 |
0.746 |
|
| 2000 |
Zong J, Pollack GM. Morphine antinociception is enhanced in mdr1a gene-deficient mice. Pharmaceutical Research. 17: 749-53. PMID 10955852 DOI: 10.1023/A:1007546719287 |
0.621 |
|
| 2000 |
Dagenais C, Rousselle C, Pollack GM, Scherrmann JM. Development of an in situ mouse brain perfusion model and its application to mdr1a P-glycoprotein-deficient mice. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 20: 381-6. PMID 10698076 DOI: 10.1097/00004647-200002000-00020 |
0.737 |
|
| 1999 |
Aquilante CL, Letrent SP, Pollack GM, Brouwer KLR. Increased brain P-glycoprotein in morphine tolerant rats Life Sciences. 66. PMID 10665989 DOI: 10.1016/S0024-3205(99)00599-8 |
0.457 |
|
| 1999 |
Letrent SP, Polli JW, Humphreys JE, Pollack GM, Brouwer KR, Brouwer KLR. P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells Biochemical Pharmacology. 58: 951-957. PMID 10509747 DOI: 10.1016/S0006-2952(99)00180-X |
0.474 |
|
| 1999 |
Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. Effects of a potent and specific P-glycoprotein inhibitor on the blood- brain barrier distribution and antinoclceptive effect of morphine in the rat Drug Metabolism and Disposition. 27: 827-834. PMID 10383928 |
0.389 |
|
| 1999 |
Chen C, Pollack GM. Enhanced antinociception of the model opioid peptide [D- Penicillamine2,5] enkephalin by P-glycoprotein modulation Pharmaceutical Research. 16: 296-301. PMID 10100317 DOI: 10.1023/A:1018892811980 |
0.408 |
|
| 1999 |
Lin PH, Waidyanatha S, Pollack GM, Swenberg JA, Rappaport SM. Dose-specific production of chlorinated quinone and semiquinone adducts in rodent livers following administration of pentachlorophenol. Toxicological Sciences : An Official Journal of the Society of Toxicology. 47: 126-33. PMID 10048161 DOI: 10.1093/Toxsci/47.1.126 |
0.318 |
|
| 1998 |
Chen C, Pollack GM. Altered disposition and antinociception of [D-penicillamine2,5] enkephalin in mdr1a-gene-deficient mice Journal of Pharmacology and Experimental Therapeutics. 287: 545-552. PMID 9808679 |
0.374 |
|
| 1998 |
Golden PL, Pollack GM. Rationale for influx enhancement versus efflux blockade to increase drug exposure to the brain. Biopharmaceutics & Drug Disposition. 19: 263-72. PMID 9604127 DOI: 10.1002/(Sici)1099-081X(199805)19:4<263::Aid-Bdd104>3.0.Co;2-4 |
0.444 |
|
| 1998 |
Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat Pharmaceutical Research. 15: 599-605. PMID 9587957 DOI: 10.1023/A:1011938112599 |
0.365 |
|
| 1997 |
Troy SM, Parker VP, Hicks DR, Pollack GM, Chiang ST. Pharmacokinetics and effect of food on the bioavailability of orally administered venlafaxine. Journal of Clinical Pharmacology. 37: 954-61. PMID 9505987 DOI: 10.1002/J.1552-4604.1997.Tb04270.X |
0.31 |
|
| 1997 |
Chen C, Pollack GM. Blood-brain disposition and antinociceptive effects of [D- penicillamine2,5]enkephalin in the mouse Journal of Pharmacology and Experimental Therapeutics. 283: 1151-1159. PMID 9399988 |
0.335 |
|
| 1997 |
Lin PH, Waidyanatha S, Pollack GM, Rappaport SM. Dosimetry of chlorinated quinone metabolites of pentachlorophenol in the livers of rats and mice based upon measurement of protein adducts Toxicology and Applied Pharmacology. 145: 399-408. PMID 9266814 DOI: 10.1006/Taap.1997.8207 |
0.321 |
|
| 1997 |
Ward KW, Blumenthal GM, Welsch F, Pollack GM. Development of a physiologically based pharmacokinetic model to describe the disposition of methanol in pregnant rats and mice Toxicology and Applied Pharmacology. 145: 311-322. PMID 9266804 DOI: 10.1006/Taap.1997.8170 |
0.325 |
|
| 1997 |
Ouellet DMC, Pollack GM. Effect of prior morphine-3-glucuronide exposure on morphine disposition and antinociception Biochemical Pharmacology. 53: 1451-1457. PMID 9260872 DOI: 10.1016/S0006-2952(97)00086-5 |
0.321 |
|
| 1997 |
Nolting A, DeLong RK, Fisher MH, Wickstrom E, Pollack GM, Juliano RL, Brouwer KL. Hepatic distribution and clearance of antisense oligonucleotides in the isolated perfused rat liver. Pharmaceutical Research. 14: 516-21. PMID 9144742 DOI: 10.1023/A:1012116003706 |
0.562 |
|
| 1997 |
Chen C, Pollack GM. Extensive biliary excretion of the model opioid peptide [D.PEN2,5]] enkephalin in rats Pharmaceutical Research. 14: 345-350. PMID 9098878 DOI: 10.1023/A:1012054222845 |
0.347 |
|
| 1996 |
Ward KW, Pollack GM. Use of intrauterine microdialysis to investigate methanol-induced alterations in uteroplacental blood flow Toxicology and Applied Pharmacology. 140: 203-210. PMID 8887435 DOI: 10.1006/Taap.1996.0214 |
0.324 |
|
| 1996 |
Gaudreault J, Varin F, Pollack GM. Anticonvulsant pharmacodynamics and disposition of triazolam in rats Journal of Pharmaceutical Sciences. 85: 999-1004. PMID 8877893 DOI: 10.1021/Js9503183 |
0.336 |
|
| 1996 |
Perkins RA, Ward KW, Pollack GM. Methanol inhalation: Site and other factors influencing absorption, and an inhalation toxicokinetic model for the rat Pharmaceutical Research. 13: 749-755. PMID 8860432 DOI: 10.1023/A:1016055701736 |
0.325 |
|
| 1996 |
Matheny CJ, Taft DR, Brouwer KL, Pollack GM. Evidence for reversible sequestration of morphine in rat liver. Biochemical Pharmacology. 52: 535-41. PMID 8759025 DOI: 10.1016/0006-2952(96)00304-8 |
0.768 |
|
| 1996 |
Booth CL, Pollack GM, Brouwer KLR. Hepatobiliary disposition of valproic acid and valproate glucuronide: Use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions Hepatology. 23: 771-780. PMID 8666331 DOI: 10.1002/Hep.510230418 |
0.305 |
|
| 1996 |
Perkins RA, Ward KW, Pollack GM. Ventilation of ambulatory rats exposed to methanol vapor in a flow- through exposure system: Measurement and input to toxicokinetic models Inhalation Toxicology. 8: 143-162. DOI: 10.3109/08958379609046560 |
0.303 |
|
| 1995 |
Perkins RA, Ward KW, Pollack GM. Comparative Toxicokinetics of Inhaled Methanol in the Female CD-1 Mouse and Sprague-Dawley Rat Fundamental and Applied Toxicology. 28: 245-254. PMID 8835234 DOI: 10.1006/Faat.1995.1165 |
0.341 |
|
| 1995 |
Ouellet DMC, Pollack GM. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats Journal of Pharmacokinetics and Biopharmaceutics. 23: 531-549. PMID 8733945 DOI: 10.1007/Bf02353460 |
0.354 |
|
| 1995 |
Perkins RA, Ward KW, Pollack GM. A pharmacokinetic model of inhaled methanol in humans and comparison to methanol disposition in mice and rats Environmental Health Perspectives. 103: 726-733. PMID 7588485 DOI: 10.1289/Ehp.95103726 |
0.317 |
|
| 1995 |
Ward KW, Perkins RA, Kawagoe JL, Pollack GM. Comparative toxicokinetics of methanol in the female mouse and rat Toxicological Sciences. 26: 258-264. DOI: 10.1006/Faat.1995.1096 |
0.342 |
|
| 1993 |
Brouwer KLR, Hall ES, Pollack GM. Protein binding and hepatobiliary distribution of valproic acid and valproate glucuronide in rats Biochemical Pharmacology. 45: 735-742. PMID 8442771 DOI: 10.1016/0006-2952(93)90149-Q |
0.325 |
|
| 1993 |
Pollack GM, Brouwer KLR, Kawagoe JL. Toxicokinetics of Intravenous Methanol in the Female Rat Toxicological Sciences. 21: 105-110. PMID 8365578 DOI: 10.1006/Faat.1993.1078 |
0.32 |
|
| 1993 |
Golden PL, Brouwer KR, Pollack GM. Assessment of valproic acid serum-cerebrospinal fluid transport by microdialysis. Pharmaceutical Research. 10: 1765-71. PMID 8302764 DOI: 10.1023/A:1018982300285 |
0.319 |
|
| 1992 |
Suttle AB, Pollack GM, Brouwer KLR. Use of a Pharmacokinetic Model Incorporating Discontinuous Gastrointestinal Absorption to Examine the Occurrence of Double Peaks in Oral Concentration–Time Profiles Pharmaceutical Research: An Official Journal of the American Association of Pharmaceutical Scientists. 9: 350-356. PMID 1614968 DOI: 10.1023/A:1015890918883 |
0.313 |
|
| 1991 |
Haberer LJ, Pollack GM. Central nervous system uptake kinetics of pentylenetetrazol in the developing rat Biopharmaceutics &Amp; Drug Disposition. 12: 59-71. PMID 2039812 DOI: 10.1002/Bdd.2510120107 |
0.378 |
|
| 1991 |
Pollack GM, Brouwer KLR. Physiologic and metabolic influences on enterohepatic recirculation: Simulations based upon the disposition of valproic acid in the rat Journal of Pharmacokinetics and Biopharmaceutics. 19: 189-225. PMID 2013839 DOI: 10.1007/Bf01073869 |
0.306 |
|
| 1991 |
Horton TL, Pollack GM. Enterohepatic recirculation and renal metabolism of morphine in the rat Journal of Pharmaceutical Sciences. 80: 1147-1152. PMID 1815073 DOI: 10.1002/Jps.2600801211 |
0.315 |
|
| 1989 |
Pollack GM, Shen DD, Dorr MB. Contribution of metabolites to the route- and time-dependent hepatic effects of di-(2-ethylhexyl)phthalate in the rat Journal of Pharmacology and Experimental Therapeutics. 248: 176-181. PMID 2913270 |
0.5 |
|
| 1986 |
Pollack GM, McHugh WB, Gengo FM, Ermer JC, Shen DD. Accumulation and washout kinetics of valproic acid and its active metabolites Journal of Clinical Pharmacology. 26: 668-676. PMID 3098806 DOI: 10.1002/J.1552-4604.1986.Tb02970.X |
0.482 |
|
| 1986 |
Shrewsbury RP, White SG, Pollack GM, Wargin WA. Antipyrine kinetics following partial blood exchange with Fluosol-DA in the rat. The Journal of Pharmacy and Pharmacology. 38: 883-7. PMID 2880960 DOI: 10.1111/J.2042-7158.1986.Tb03376.X |
0.314 |
|
| 1986 |
Shen DD, Pollack GM. Reply Toxicology and Applied Pharmacology. 82: 384-385. DOI: 10.1016/0041-008X(86)90217-6 |
0.395 |
|
| 1985 |
Pollack GM, Buchanan JF, Slaughter RL, Kohli RK, Shen DD. Circulating concentrations of di(2-ethylhexyl) phthalate and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. Toxicology and Applied Pharmacology. 79: 257-67. PMID 4002227 DOI: 10.1016/0041-008X(85)90347-3 |
0.476 |
|
| 1985 |
Pollack GM, Li RCK, Ermer JC, Shen DD. Effects of route of administration and repetitive dosing on the disposition kinetics of di(2-ethylhexyl) phthalate and its mono-de-esterified metabolite in rats Toxicology and Applied Pharmacology. 79: 246-256. PMID 4002226 DOI: 10.1016/0041-008X(85)90346-1 |
0.505 |
|
| 1985 |
Pollack GM, Shen DD. A timed intravenous pentylenetetrazol infusion scizure model for quantitating the anticonvulsant effect of valproic acid in the rat Journal of Pharmacological Methods. 13: 135-146. PMID 3920448 DOI: 10.1016/0160-5402(85)90057-9 |
0.47 |
|
| 1984 |
Pollack GM, Li RCK, Shen DD. Dose-dependent pharmacokinetics of antipyrine in the rat Research Communications in Chemical Pathology and Pharmacology. 44: 69-81. PMID 6729251 |
0.474 |
|
| 1984 |
Pollack GM, Shen DD. Effect of renal failure and Bis(2‐ethylhexyl) phthalate pretreatment on the disposition and metabolism of antipyrine in the rat Journal of Pharmaceutical Sciences. 73: 29-33. PMID 6694077 DOI: 10.1002/Jps.2600730108 |
0.469 |
|
| 1984 |
Pollack GM, Slaughter RL, Buchanan JF, Shen DD. High-performance liquid chromatographic procedure for the determination of di-(2-ethylhexyl)phthalate in human blood specimens. Problems of variable-extraction yield and the use of standard addition for calibration. Journal of Chromatography. 311: 101-8. PMID 6520150 DOI: 10.1016/S0378-4347(00)84695-2 |
0.434 |
|
| 1984 |
Shen DD, Pollack GM. A reply to 'Problems involved with developing a suitable model for evaluating exposure to bis(2-ethylhexyl) phthalate from medical devices Journal of Pharmaceutical Sciences. 73: 1334-1335. PMID 6491968 DOI: 10.1002/Jps.2600730945 |
0.481 |
|
| 1984 |
Pollack GM, Baswell B, Szefler SJ, Shen DD. Comparison of inter- and intra-subject variation in oral absorption of theophylline from sustained-release products International Journal of Pharmaceutics. 21: 3-16. DOI: 10.1016/0378-5173(84)90198-4 |
0.433 |
|
| Show low-probability matches. |
